SCHEMBL4014159

SCHEMBL4014159

Clc1cccc2c(Br)ccnc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.61
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
HTT P42858 5/20 0.46
TDP1 Q9NUW8 4/20 0.46
MAPT P10636 4/20 0.46
HSP90AA1 P07900 4/20 0.46
TP53 P04637 3/20 0.46
USP2 O75604 2/20 0.46
APAF1 O14727 1/20 0.46
TDP2 O95551 1/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
MAP4K4 O95819 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29777332 0.84 KMT2A (0.59) NR4A2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL18980424 0.84 KMT2A (0.59) NR4A2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL29410781 0.81 NR4A2 (0.68) NR4A2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL318769 0.81 NR4A2 (0.68) NR4A2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL17502507 0.76 KDM4E (0.59) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL4013888 0.76 HTR1A (0.56) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL29933523 0.76 KDM4E (0.46) NR4A2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL21852023 0.76 MEN1 (0.70) NR4A2KDM4EALDH1A1SMN1; SMN2MEN1
SCHEMBL29779858 0.76 KDM4E (0.59) KDM4EALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5764170 0.76 KMT2A (0.46) NR4A2KDM4EALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289826-A1 PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF TSINGHUA UNIVERSITY (CN) 2025-09-18 US disclosed
EP-4055014-B1 PYRROLIDINE AND PIPERIDINE COMPOUNDS YUHAN CORP (KR) 2025-04-30 EP disclosed
EP-4509494-A1 PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF Tsinghua University (CN) 2025-02-19 EP disclosed
CN-114867719-B Pyrrolidine and piperidine compounds 柳韩洋行 2024-06-25 CN disclosed
WO-2023208171-A1 PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF 清华大学 2023-11-02 WO disclosed
US-11655235-B2 Pyrrolidine and piperidine compounds YUHAN CORPORATION (KR) 2023-05-23 US disclosed
EP-4055014-A1 PYRROLIDINE AND PIPERIDINE COMPOUNDS Yuhan Corporation (KR) 2022-09-14 EP disclosed
CN-114867719-A Pyrrolidine and piperidine compounds 柳韩洋行 2022-08-05 CN disclosed
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2022-07-07 US disclosed
US-11312723-B2 Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases THE ROCKEFELLER UNIVERSITY (US) 2022-04-26 US disclosed
EP-3716972-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES The Rockefeller University (US) 2020-10-07 EP disclosed
CN-111670034-A Pyranopyrazoles and pyrazolopyridines immunomodulators for the treatment of autoimmune diseases 洛克菲勒大学 2020-09-15 CN disclosed
US-20190202811-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2019-07-04 US disclosed
EP-3463341-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES The Rockefeller University (US) 2019-04-10 EP disclosed
WO-2017205296-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2017-11-30 WO disclosed
WO-2017205296-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES THE ROCKEFELLER UNIVERSITY (US) 2017-11-30 WO disclosed
CN-101541751-A Quinoline compounds WYETH CORP (US) 2009-09-23 CN disclosed
EP-2074098-A2 QUINOLINE COMPOUNDS Wyeth (US) 2009-07-01 EP disclosed
WO-2008049047-A2 QUINOLINE COMPOUNDS WYETH (US) 2008-04-24 WO disclosed
US-4801717-A PLANT GROWTH REGULATORS ROUSSEL UCLAF (FR) 1989-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11312723-B2 Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases TFPI, TFPI2, SERPINC1 NR4A2 2647/4885KDM4E 3175/4885ALDH1A1 1832/4885
US-20220213114-A1 PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI, TFPI2, SERPINC1 NR4A2 2647/4885KDM4E 3175/4885ALDH1A1 1832/4885
US-11655235-B2 Pyrrolidine and piperidine compounds FAP, APC, VHL NR4A2 4403/4885KDM4E 1644/4885ALDH1A1 439/4885
US-20190202811-A1 AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES TFPI2, IL4I1, TFPI NR4A2 3083/4885KDM4E 1114/4885ALDH1A1 2068/4885
US-20250289826-A1 PLPRO PROTEIN INHIBITOR, AND PREPARATION METHOD AND APPLICATION THEREOF ACE, PLP2, ACE2 NR4A2 4471/4885KDM4E 3550/4885ALDH1A1 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.